These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38625661)

  • 21. Ruxolitinib (Opzelura) for atopic dermatitis.
    Med Lett Drugs Ther; 2022 Jan; 64(1642):12-13. PubMed ID: 35134043
    [No Abstract]   [Full Text] [Related]  

  • 22. JAK inhibitors for the treatment of vitiligo.
    Inoue S; Suzuki T; Sano S; Katayama I
    J Dermatol Sci; 2024 Mar; 113(3):86-92. PubMed ID: 38326166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel Clinical Applications of Topical Ruxolitinib: A Case Series.
    Zundell MP; Al-Dehneem R; Song T; Yousif J; Gottlieb AB
    J Drugs Dermatol; 2024 Mar; 23(3):188-190. PubMed ID: 38443119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study.
    Kim BS; Sun K; Papp K; Venturanza M; Nasir A; Kuligowski ME
    J Am Acad Dermatol; 2020 Jun; 82(6):1305-1313. PubMed ID: 32057960
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utilization of Topical Ruxolitinib in Dermatology: A Review.
    Kashetsky N; Turchin I
    Skin Therapy Lett; 2023 May; 28(3):8-13. PubMed ID: 37339609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies.
    Simpson EL; Bissonnette R; Chiesa Fuxench ZC; Kallender H; Sturm D; Ren H; Stein Gold LF
    J Dermatolog Treat; 2024 Dec; 35(1):2310633. PubMed ID: 38297490
    [No Abstract]   [Full Text] [Related]  

  • 27. Off-label Studies on the Use of Ruxolitinib in Dermatology.
    Tegtmeyer K; Ravi M; Zhao J; Maloney NJ; Lio PA
    Dermatitis; 2021 May-Jun 01; 32(3):164-172. PubMed ID: 33443378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of topical ruxolitinib cream for the treatment of vitiligo: A systematic review and meta-analysis of randomized controlled trials.
    Ehsan M; Rehman AU; Ayyan M; Cheema HA; Ahmad TZ; Mustafa B; Shahid A; Khedro T; Ismail H; Nashwan AJ
    J Cosmet Dermatol; 2024 Jan; 23(1):350-353. PubMed ID: 38161317
    [No Abstract]   [Full Text] [Related]  

  • 29. Ruxolitinib cream for the short-term treatment of mild-moderate atopic dermatitis.
    Krajewski PK; Szepietowski JC
    Expert Rev Clin Immunol; 2023 Apr; 19(4):349-356. PubMed ID: 36542765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
    Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
    Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.
    Devos T; Selleslag D; Granacher N; Havelange V; Benghiat FS
    Hematology; 2022 Dec; 27(1):23-31. PubMed ID: 34957926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis.
    Blauvelt A; Kircik L; Papp KA; Simpson EL; Silverberg JI; Kim BS; Kwatra SG; Kuligowski ME; Venturanza ME; Wei S; Szepietowski JC
    J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):137-146. PubMed ID: 36066323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis.
    Bissonnette R; Call RS; Raoof T; Zhu Z; Yeleswaram S; Gong X; Lee M
    Am J Clin Dermatol; 2022 May; 23(3):355-364. PubMed ID: 35368221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinically relevant improvements in adults and adolescents with atopic dermatitis who did not achieve Investigator's Global Assessment treatment success following 8 weeks of ruxolitinib cream monotherapy.
    Simpson EL; Kircik L; Blauvelt A; Kallender H; Kuo Y; Ren H; Sturm D; Eichenfield LF
    J Dermatol; 2023 Dec; 50(12):1523-1530. PubMed ID: 37830436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies.
    Papp K; Szepietowski JC; Kircik L; Toth D; Eichenfield LF; Leung DYM; Forman SB; Venturanza ME; Sun K; Kuligowski ME; Simpson EL
    J Am Acad Dermatol; 2021 Oct; 85(4):863-872. PubMed ID: 33957195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis.
    Kirito K; Okamoto S; Ohishi K; Tauchi T; Handa H; Saito S; Takenaka K; Shimoda K; Oritani K; Akashi K; Okada H; Amagasaki T; Suzuki K; Yonezu T; Komatsu N
    Int J Hematol; 2018 Jan; 107(1):92-97. PubMed ID: 28986762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
    Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
    JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study.
    Bokhari L; Sinclair R
    Int J Dermatol; 2018 Dec; 57(12):1464-1470. PubMed ID: 30160787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of aryl hydrocarbon receptor agonists in the treatment of vitiligo.
    Bitterman D; Kabakova M; Wang JY; Collins A; Patel P; Gupta N; Zafar K; Cohen M; Jagdeo J
    Arch Dermatol Res; 2024 Oct; 316(9):659. PubMed ID: 39369105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis.
    Phan K; Phan S; Shumack S; Gupta M
    J Dermatolog Treat; 2022 Feb; 33(1):173-177. PubMed ID: 32096671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.